UroGen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Guggenheim Analyst Says
UroGen Pharma (NASDAQ:URGN – Free Report) had its price target upped by Guggenheim from $15.00 to $30.00 in a research note published on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other equities research analysts have also recently commented on URGN. LADENBURG THALM/SH SH initiated coverage on UroGen Pharma […]
UroGen Pharma (NASDAQ:URGN – Free Report) had its price target upped by Guggenheim from $15.00 to $30.00 in a research note published on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other equities research analysts have also recently commented on URGN. LADENBURG THALM/SH SH initiated coverage on UroGen Pharma […]
